Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 4:03 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: GVHD, Acute Clear all
Completed Phase 2 Interventional

Norketotifen for the Treatment of Uncomplicated Influenza-like Illness

NCT04043923
View directory record Official record
Conditions
Influenza -Like Illness
Interventions
Norketotifen, Placebo
Drug
Lead sponsor
Emergo Therapeutics, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Benralizumab
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
9
States / cities
Tampa, Florida • Springfield, Massachusetts • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia

NCT00005596
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, leucovorin calcium, mercaptopurine, methotrexate, pegaspargase, thioguanine, vincristine sulfate
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
1,076 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
108
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Not listed Not applicable Interventional

Daily Intermittent Hypoxia and Task-Specific Upper Limb Training in Persons With Chronic Incomplete SCI

NCT03262766
View directory record Official record
Conditions
Spinal Cord Injuries
Interventions
Acute Intermittent Hypoxia (AIH), Upper extremity training, Sham Acute intermittent hypoxia
Other · Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 70 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 18, 2020 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

Virtual Reality Distraction for Reduction

NCT04416555
View directory record Official record
Conditions
Postoperative Pain
Interventions
Placebo comparator: VR googles and the non reality experience, Active Comparator: VR googles and the real VR program to enter act with and experience
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 85 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Not applicable Interventional

Moderate Intensity Exercise and Phenylketonuria

NCT01904708
View directory record Official record
Conditions
Phenylketonuria, PKU
Interventions
Acute Moderate Intensity Exercise
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
14 Years to 17 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Repeated Doses of DX-88 (Ecallantide) to Treat Attacks of Hereditary Angioedema (HAE)

NCT00456508
View directory record Official record
Conditions
Hereditary Angioedema (HAE)
Interventions
ecallantide
Drug
Lead sponsor
Shire
Industry
Eligibility
10 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • Berkeley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting No phase listed Observational

Knee Related Subchondral Bone Lesions Treated With IOBP

NCT05314608
View directory record Official record
Conditions
Subchondral Cyst
Interventions
IntraOsseous BioPlasty® (IOBP®) Surgical Technique into the knee
Combination Product
Lead sponsor
Arthrex, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Denver, Colorado • Gulf Breeze, Florida • Salisbury, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Sep 24, 2026, 4:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sickle Cell Pro-Inflammatory Response to Interval Training Study

NCT03653676
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Exercise Test (CIIT)
Other
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
10 Years to 21 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Chicago, Illinois • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 24, 2026, 4:03 PM EDT
Withdrawn Not applicable Interventional

Assessment of Occult Lung Stress During Lung Protective Mechanical Ventilation

NCT05675696
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome
Interventions
Esophageal Catheter
Other
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2025 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

NCT02582203
View directory record Official record
Conditions
Skin Diseases, Infectious, Staphylococcal Skin Infections
Interventions
Ceftaroline, Vancomycin
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 31, 2016 · Synced Sep 24, 2026, 4:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Pulse Oximetry_Performance Testing- PCBA-1 (Printed Circuit Board Assembly)

NCT01747460
View directory record Official record
Conditions
Healthy
Interventions
Not listed
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Boulder, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 5, 2013 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

NCT04103879
View directory record Official record
Conditions
High Risk Hematological Malignancy, Cord Blood Transplant
Interventions
ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Biological
Lead sponsor
ExCellThera inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Aurora, Colorado • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Heritable Connective Tissue Disorders

NCT00001641
View directory record Official record
Conditions
Connective Tissue Disease, Dissecting Aneurysm, Ehlers Danlos Syndrome, Marfan Syndrome, Nail Patella Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of SP-103 in Subjects With Moderate to Severe Acute Lower Back Pain

NCT05096494
View directory record Official record
Conditions
Moderate to Severe Acute Lower Back Pain
Interventions
SP-103, Placebo
Drug
Lead sponsor
Scilex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
10
States / cities
Phoenix, Arizona • Fernandina Beach, Florida • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

NCT04588922
View directory record Official record
Conditions
Hematologic Malignancies
Interventions
SLS009, venetoclax, azacitidine
Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
12 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
19
States / cities
Birmingham, Alabama • Goodyear, Arizona • Phoenix, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine

NCT02605174
View directory record Official record
Conditions
Migraine With or Without Aura
Interventions
Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
3,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
95
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2019 · Synced Sep 24, 2026, 4:03 PM EDT
Recruiting Not applicable Interventional

Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia

NCT06710418
View directory record Official record
Conditions
Acute Myeloid Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Myeloid Neoplasm
Interventions
Activity Tracking, Biospecimen Collection, Cognitive Assessment, Electronic Health Record Review, Packed Red Blood Cell Transfusion, Quality-of-Life Assessment
Other · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Acute D2 Receptor Blockade Induced Neuronal Network Changes in Human Volunteers

NCT01931059
View directory record Official record
Conditions
Imaging of the Brain and Antipsychotics, Neuronal Network Changes
Interventions
Risperidone, Placebo
Drug · Other
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2018 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

NCT03870880
View directory record Official record
Conditions
Schizophrenia
Interventions
Risperidone ISM 75 mg, Risperidone ISM 100 mg
Drug
Lead sponsor
Rovi Pharmaceuticals Laboratories
Industry
Eligibility
18 Years to 65 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
13
States / cities
Rogers, Arkansas • Garden Grove, California • Long Beach, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 3 Interventional

SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism

NCT00062803
View directory record Official record
Conditions
Pulmonary Embolism
Interventions
SR34006, (LMW)heparin, Warfarin VKA, Acenocoumarol VKA
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
54
States / cities
Loma Linda, California • San Diego, California • Aurora, Colorado + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2009 · Synced Sep 24, 2026, 4:03 PM EDT
Terminated Phase 2 Interventional

Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match

NCT01500161
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Hodgkins Disease, Non-Hodgkins Lymphoma, Aplastic Anemia, Multiple Myeloma, Myelodysplastic Syndrome
Interventions
Busulfan, Clofarabine, Fludarabine, Melphalan, Carmustine, Etoposide, Cytarabine
Drug
Lead sponsor
Texas Oncology Cancer Center
Industry
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Not applicable Interventional Results available

Aspiration in Acute Respiratory Failure Survivors

NCT02363686
View directory record Official record
Conditions
Dysphagia
Interventions
FEES, BSE
Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
3
States / cities
Aurora, Colorado • New Haven, Connecticut • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2021 · Synced Sep 24, 2026, 4:03 PM EDT
Completed Phase 2 Interventional

TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid

NCT03397173
View directory record Official record
Conditions
Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Acute Myeloid Leukemia
Interventions
Azacitidine, Ascorbic acid
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 10, 2021 · Synced Sep 24, 2026, 4:03 PM EDT